Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 5/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17335723 | 0.99 | EPHX2 (0.54) | EPHX2TRPV1FAAHCNR1CNR2 | |
| SCHEMBL9787236 | 0.86 | EPHX2 (0.56) | EPHX2TRPV1FAAHCNR1CNR2 | |
| SCHEMBL17335671 | 0.86 | AOC3 (0.45) | ALDH1A1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17335644 | 0.83 | LMNA (0.41) | EPHX2TRPV1ALDH1A1CYP3A4HPGD | |
| SCHEMBL17335684 | 0.81 | LMNA (0.43) | EPHX2ALDH1A1CYP3A4HPGDALOX15 | |
| SCHEMBL15007831 | 0.79 | EPHX2 (0.79) | EPHX2TRPV1FAAHCNR1CNR2 | |
| SCHEMBL15008342 | 0.79 | EPHX2 (0.79) | EPHX2TRPV1FAAHCNR1CNR2 | |
| SCHEMBL2762512 | 0.79 | EPHX2 (0.79) | EPHX2TRPV1FAAHCNR1CNR2 | |
| SCHEMBL406015 | 0.79 | EPHX2 (0.79) | EPHX2TRPV1FAAHCNR1CNR2 | |
| SCHEMBL2761734 | 0.79 | EPHX2 (0.79) | EPHX2TRPV1FAAHCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | claimed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | EPHX2 2649/4885TRPV1 111/4885FAAH 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.